martes, 26 de abril de 2011

Desmitificando el costo de desarrollo de un nuevo medicamento.





Historia de una exageración...

o...de como 800 millones de dólares se convierten en tan solo...59.4









Se cansaron de exagerarnos las cifras...


Las "indexaron" a su antojo...



Marcia Angel (en The Truth about the drug companies) "desbarató" sus argumentos...


Ahora...la "cruda realidad" ) 59.4 millones de $...




Clik sobre imagen para ampliar

Gracias a la "disciplina académica" de...

Donald Light is Lokey visiting professor at Stanford University and a professor of comparative health-care at the University of Medicine and Dentistry of New Jersey. He is an economic and organizational sociologist who studies health care systems and pharmaceutical policy. As a founding fellow of the Center for Bioethics, he has become concerned about exaggerated claims of risk, cost, and benefit of new medicines that result in misguided policies. Professor Light is co-author and editor of The Risks of Prescription Drugs (2010).
His research has appeared in leading medical and social science journals.

RebeccaWarburton is an associate professor and a health economist, specializing in the cost/benefit analysis of health-related public projects. Her current research primarily concerns assessing the validity of industry-sponsored estimates of the cost of drug development, and assessing the costs and effects of patient safety improvements. She has a PhD in economics from the University of London (1995), and an M.Sc. in economics from the London School of Economics (1980). Before coming to the University of Victoria in 1998, she worked for 10 years as a policy analyst and program evaluator for the British Columbia Ministry of Health.

Publicado por
London School of Economics and Political Science

Publicar un comentario